


Vandetanib Fumarate

Chemical Properties

CAS No. :	338992-00-0
Formula:	C ₂₆ H ₂₈ BrFN ₄ O ₆
Molecular Weight:	591.43
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Vandetanib Fumarate is an orally available tyrosine kinase inhibitor. Vandetanib Fumarate works by blocking RET (REarranged during Transfection), vascular endothelial growth factor receptor (VEGFR-2, VEGFR-3), and epidermal growth factor receptor and to a lesser extent VEGFR-1, which are important targets in thyroid cancer (TC).
Targets(IC50)	Others

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.6908 mL	8.4541 mL	16.9082 mL
5 mM	0.3382 mL	1.6908 mL	3.3816 mL
10 mM	0.1691 mL	0.8454 mL	1.6908 mL
50 mM	0.0338 mL	0.1691 mL	0.3382 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Fallahi P, Di Bari F, Ferrari SM, Spisni R, Materazzi G, Miccoli P, Benvenga S, Antonelli A. Selective use of vandetanib in the treatment of thyroid cancer. *Drug Des Devel Ther.* 2015 Jul 3;9:3459-70. doi: 10.2147/DDDT.S72495.

eCollection 2015. Review. PubMed PMID: 26170630; PubMed Central PMCID: PMC4498730.

Cooper MR, Yi SY, Alghamdi W, Shaheen DJ, Steinberg M. Vandetanib for the treatment of medullary thyroid carcinoma. *Ann Pharmacother.* 2014 Mar;48(3):387-94. doi: 10.1177/1060028013512791. Epub 2013 Nov 14.

Review. PubMed PMID: 24259657.

Fallahi P, Ferrari SM, Baldini E, Biricotti M, Ulisse S, Materazzi G, Miccoli P, Antonelli A. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer. *Expert Rev Anticancer Ther.* 2016 Nov;16(11):1109-1118. Epub 2016 Sep 30. Review. PubMed PMID: 27650489.

De Luca A, D'Alessio A, Maiello MR, Gallo M, Bevilacqua S, Frezzetti D, Morabito A, Perrone F, Normanno N.

Vandetanib as a potential treatment for breast cancer. *Expert Opin Investig Drugs.* 2014 Sep;23(9):1295-303. doi: 10.1517/13543784.2014.942034. Epub 2014 Aug 4. Review. PubMed PMID: 25089348.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481